Listen to this episode on:
In this episode of Power to the Patients, Brandon Li sits down with Srinivas Rao, Co-CEO of atai Life Sciences, for a deep dive into the pragmatic strategies shaping the future of psychedelic therapies. Srini shares how his background in engineering and neuropharmacology has informed a streamlined, patient-centric approach to drug development.
Key topics include:
- The evolution of atai Life Sciences: How they evolved from a fund to a biotech company.
- Innovative drug delivery approaches: Exploring novel formulations like DMT oral thin films, and why simplicity and scalability matter.
- Development strategy: Balancing diverse compounds and therapeutic areas with a focused portfolio strategy.
- New horizons: Advancing research in areas like social anxiety disorder and cognitive impairment in schizophrenia.
- Clinical trial challenges: Tackling challenges such as the placebo effect and trial design complexities.
Tune in to hear how a pragmatic lens is redefining what’s possible in neuropsychiatric drug development.
Related Podcasts
Subscribe to Power's Newsletter
Stay ahead with a new patient recruitment insight every week.